Search

Displaying results 1191 - 1200 of 10000 in total
  1. Drug

    Sodium phosphate, dibasic

    go.drugbank.com/drugs/DB14502
    ApprovedInvestigational

    Mixtures: Aminosyn II 7% M In 10% Dextrose(dual Chamber), Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)
  2. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.

    Synonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
  3. Drug

    Coagulation factor X human

    go.drugbank.com/drugs/DB13148
    ApprovedInvestigational

    However its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency. … While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways.

    Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET
  4. Drug

    Nafcillin

    go.drugbank.com/drugs/DB00607
    ApprovedInvestigational

    It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections [A20360]. … It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA.

  5. Drug

    Artesunate

    go.drugbank.com/drugs/DB09274
    ApprovedInvestigational

    Artesunate is indicated for the initial treatment of severe malaria.[L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria. … [A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]

  6. Drug

    Ribavirin

    go.drugbank.com/drugs/DB00811
    ApprovedInvestigational

    as an adjunct therapy to various first-line and second-line combination therapies recommended for each genotypes. … Combination therapy of ribavirin and [DB00008] results in the SVR of 44% in patients with genotype 1 infection and 70% in patients with genotype 2-6.

    Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)
  7. Drug

    Racemethionine

    go.drugbank.com/drugs/DB13972
    Approved

    A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.

    Mixtures: Card-floe II Tab, Nephramine Liq IV
  8. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one … Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.

  9. Drug

    Gemfibrozil

    go.drugbank.com/drugs/DB01241
    ApprovedInvestigational

    [A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. … Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.

  10. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    It was granted approval by FDA in August 2017 under the market name Kymriah. … In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent